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Abstract
Three novel steroidal antiestrogen-geldanamycin conjugates were prepared using a convergent
strategy. The antiestrogenic component utilized the 11β-(4-functionalized-oxyphenyl) estradiol
scaffold, while the geldanamycin component was derived by replacement of the 17-methoxy
group with an appropriately functionalized amine. Ligation was achieved in high yield using azide
alkyne cyclization reactions. Evaluation of the products against two breast cancer cell lines
indicated that the conjugates retained significant antiproliferative activity.
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Introduction
Breast cancer is the most prevalent form of cancer in women and the well-established
association between the human estrogen receptor (ER) and cell proliferation provided the
basis for endocrine (antihormonal) therapy.1,2 However, prolonged treatment with
antiestrogens often results in the development of hormonal resistance, leading to recurrence
of the disease and the use of more potent, but nonselective, therapeutic agents.3–5 One
strategy that attempts to circumvent the effects of resistance is the use of drug conjugates in
which two therapeutic agents are combined into a single entity.6–8
As part of our program in breast cancer research, we have focused on using ER as a
targeting mechanism for which the steroidal anti-estrogenic component may also provide a
beneficial therapeutic response. The choice of the therapeutic component is also critical as it
should not only be active within the same concentration range as the hormonal component
but exert a complementary or synergistic effect. The ER-targeting component was
developed in our initial work with the 11β-(4-substituted-oxyphenyl) estradiols.9,10 Based
on the affinity of the steroids for the ER and their antiestrogenic activity, we prepared a
steroidal antiestrogen-mitomycin C conjugate to test our concept.11 Although the compound
retained high ER affinity and antiestrogenic properties, it was no more active than
mitomycin C and displayed no selectivity toward ER-expressing breast cancer cells. One
possible explanation for the lack of synergy may have involved the properties of the linker.
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Unfortunately, issues regarding the availability mitomycin C precluded further studies with
this conjugate. Therefore we elected to evaluate the effect of linker length and
conformational flexibility using the Hsp90 N-terminal inhibitor, geldanamycin (GDA), as
the therapeutic component. [Figure 1]
Heat shock proteins (HSP) are molecular chaperones that are critical for the maintenance of
cellular homeostasis through regulation of protein transport, conformational folding and
maturation12. Hsp90 is a 90kDa protein that is often overexpressed in breast cancer, as well
as other cancers, and, as a result of these increased levels, is responsible for maintaining
high levels of active oncogenic proteins13,14,15. One of these proteins is ERα which, when
dormant, is confined to the nucleus in an Hsp90 complex16. Disruption of the Hsp90-ERα
complex leads to improper folding of ERα and its subsequent degradation, resulting in
down-regulation of its corresponding pathways, such as transcription. Therefore, disruption
of Hsp90-mediated responses provides an alternative target for breast cancer therapy, and
has led to the use of geldanamycin (GDA) and its derivatives as therapeutic agents.
The geldanamycin component was developed based upon our work with chaperone
inhibiting agents. Structure- activity relationship studies demonstrated that modification at
the 17-position not only generates GDA derivatives that exhibit reduced toxicity, but this
position is also substituent tolerant as groups at this position of GDA exit the Hsp90 binding
pocket and thus do not significantly affect inhibitory activity17. Other 17-GDA derivatives
have been synthesized that exhibit improved solubility and lower toxicity than GDA, but are
still hepatotoxic18,19. Therefore we planned to introduce modifications at the 17-postion that
will permit conjugation to the steroidal derivatives.
We chose a convergent approach in which each component contained a side chain that is
terminally substituted with a reactive functionality. The final step then involves a ligation
reaction under mild conditions. The reaction selected for this study was the Huisgen [3+2]
cycloaddition reaction between a terminal azide and a terminal alkyne to generate a
chemically stable triazole moiety.20–22 The reaction has the advantage of being
chemoselective and allowing the reactive groups to reside on either component. In this study
we chose to use different lengths of the linker to investigate what effect, if any, it exerts on
the biological activity of the final conjugate. The overall synthetic strategy for our
conjugates is shown in Figure 2.
Results
The synthesis of the steroidal antiestrogen component was accomplished using a strategy
similar to one described for our 11β-(4-substituted oxyphenyl) estradiols.9,10 Deltenone 3-
ethylene ketal 1 was converted initially to the 11β-(4-hydroxyphenyl) estra-4,9-diene-3,17-
dione 2. This compound then served as the intermediate for the preparation of the requisite
11β-(4-azidoethoxyphenyl)estradiol 4a and 11β-(4-N-propargyl-N-
methylaminoethoxyphenyl) estradiol components 4b. For the propargyl derivative, we
prepared the 2-(N-propargyl-N-methylamino)ethanol which was then coupled to the 11β-(4-
hydroxyphenyl) estra-4,9-diene-3,17-dione 2 using the Mitsunobu reaction to give 3b.
Aromatization with acetic anhydride-acetyl bromide followed by reduction-saponification
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gave the desired product 4b. Overall yields for the two compounds were 28% (8 steps) and
19% (7 steps) respectively. We had previously characterized the azido derivative 4a,
determined its binding affinity (RBA= 39 %) and showed that it was a full antagonist of
ERα. The N-propargyl-N-methyl derivative 4b is a close analog of the RU39411 for which
we had determined ER affinity (RBA = 39%) and efficacy (full antagonism). Having
demonstrated that additional substituents distal to the nitrogen in the side chain did not
adversely affect either binding or efficacy, we felt that the steroidal components were
appropriate substrates for subsequent ligation reactions.10
The geldanamycin components were prepared using variations of methods previously
described for 17-amino derivatives.15, 23 Treatment of geldanamycin 5 with either propargyl
amine or ώ-azido pentaethylene glycol amine in dichloromethane gave the corresponding
17-amino geldanamycin components 6a and 6b in 80% and 68% yields respectively. For the
third geldanamycin component, a two step procedure was used, similar to that employed in
our previous preparation of the biotinylated derivative. Geldanamycin 5 was initially treated
with a 5-fold excess of 1,5-pentanediamine in dichloromethane. Purification by column
chromatography gave the 17-(5-aminopentyl)amino geldanamycin 6c in a 95% yield.
Bertozzi’s difluoro-cyclooctyne carboxylic acid24 was converted to the corresponding acyl
chloride and immediately reacted with 17-(5-aminopentyl)amino geldanamycin 6c to form
the corresponding amide 6d. The product was isolated in a 42% yield following column
chromatography.
Ligation to form the final antiestrogen-geldanamycin conjugates used two versions of the
“click” reaction. In the conventional version, we used the 17-propargylamino geldanamycin
6a and the 11β-(4-azidoethoxyphenyl) estradiol 4a as coupling partners to give the 1,2,3-
triazole conjugate 7a with a short linker in a 46 % isolated yield. Coupling the 17-
(azidopentaethylene glycolamino) geldanamycin 6b with 11β-(4-N-propargyl-N-
methylaminoethoxyphenyl) estradiol 4b under the same conditions gave the triazole
conjugate 7b with a longer linker in 47 % isolated yield. The third conjugate was prepared
from the cyclooctynylated amino geldanamycin 6d and 11β-(4-azidoethoxyphenyl) estradiol
4a in which the copperless-method gave the corresponding annulated triazole 7c in a 73 %
isolated yield.
The three new conjugates and geldanamycin were evaluated for antiproliferative activity
against MCF-7 and SKBr3 breast cancer cell lines. (Table 1) In this assay, the
antiproliferative activity of geldanamycin 5 in the two cell lines was determined to be 9.8
and 8.5 nM respectively. Conjugate 7a with the shortest linker group manifested an IC50 of
1150 ± 90 nM in MCF-7 and 710 ± 160 nM in SKBr3 cells. Conjugate 7b with the longer
linker was more potent with IC50 values of 102 ± 4.6 nM and 41 ± 4.6 in the respective cell
lines. Conjugate 7c that incorporated the bulkier Bertozzi linker had an IC50 value of 15200
± 3000 nM in MCF-7 cells and was not therefore evaluated in the SKBr3 cell line. The
results indicated that while all of the new conjugates retained significant antiproliferative
activity, however, the potency was clearly modulated by the additional linker and
antiestrogen components.
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The objectives of this study were to evaluate the effects of the linker on the antiproliferative
activity of the antiestrogen-drug conjugate. We had observed in our initial study with a
antiestrogen-mitomycin C conjugate that a long, linear oligoethylene glyocol linker retained
high ER binding affinity (RBA = 7%), similar to the effects observed previously by
Essigmann, et al with their 7α- derivatives.25 In that study, the antiproliferative activity of
the conjugate was comparable to that of the parent mitomycin C.11 In this study, the two
conjugates 7a and 7b having the least sterically constrained linkers were also the most
potent compounds. The conjugate 7c, having the cyclooctyl triazole closest to the 11β
position of estradiol was most likely to produce significant steric interactions with the
estrogen receptor which would compromise the targeting toward ER-expressing cells. The
results suggest that the accessibility of the antiestrogenic component for the target
membrane ER may influence the overall potency. The least sterically demanding conjugate
7b is an order of magnitude more potent than the conjugate with the shorter linker 7a which
is an order of magnitude more potent than the sterically compromised conjugate 7c.
The linker component may also affect the therapeutic activity. Previous studies indicated
that geldanamycin forms a stable complex with Hsp90 via a complex set of interactions that
are modulated by substituents at the 17-position. With the 17-amino-17-desmethoxy
derivatives, the exit site for this group corresponds to the heteroatom and therefore the
length of the group would be expected to affect the biological response. In this study, two
conjugates 7a and 7b display sub-micromolar activity against ER-expressing cells, although,
both compounds are more active against the SKBr3 breast cancer cells that do not express
ER. In those cells, conjugate 7b, having the longer linker, while less potent than
geldanamycin alone, is more than an order of magnitude more potent than 7a, the conjugate
with the shorter linker. Activity of the more complex conjugate 7c was not determined, but
the results suggest that the longer, more conformationally flexible linkers are favored at the
17-position.
The results suggest that ER-targeting was not the major factor underlying the biological
effectiveness of the conjugates. If ER-targeting were the major component, one would
expect thet cytotoxicity to be greater in MCF-7 cells as opposed to the SKBr3 cells. This
response pattern was observed with our steroidal antiestrogen-mitomycin C conjugate in
which ER-based selectivity was not achieved, even though the ER binding affinity for the
conjugate was relatively high.25 For the two most active conjugates 7a and 7b, activity was
greater in the SKBr3 cells than in the MCF-7, a pattern that was similar to geldanamycin
alone. Therefore it appears that the overall antiproliferative responses were modulated by the
presence of the steroidal components, but did not enhance the overall effect compared to
geldanamycin. It should be noted that the desired response pattern was observed for our
doxorubicin-antiestrogen conjugate that we recently described in which MCF-7
antiproliferative activity was enhanced compared to doxorubicin alone and almost seven-
fold greater than that observed in MDA-MB-231 cells which are ER-negative.26
One of the significant differences between our doxorubicin-antiestrogen conjugate and the
current series of geldamycin conjugates is that the former contain a component that allows
the drug to dissociate within cancer cells. As with the mitomycin C conjugate, the synthetic
strategy used in this study did not incorporate that property. It is possible that for these
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conjugates that cellular uptake may be mediated via the membrane estrogen receptor but that
effective intracellular distribution requires dissociation of the therapeutic component from
the antiestrogen targeting group. Continued association with the antiestrogen component
may reduce the effectiveness of the drug from accessing its site of action, even if elevated
intracellular concentrations are obtained. Oligoethylene glycol linkes, such as those used in
7b and the doxorubicin-anitestrogen conjugate, may also contribute physicochemical
properties that enhance cellular uptake. Because of the potent antiproliferative activity
observed for 7b, incorpoaration of a linker that can impart both properties may generate the
desired biological effect.
In conclusion, we have described a convergent strategy for the preparation of a novel series
of novel steroidal antiestrogen-drug conjugates. This approach has distinct advantages in
preparing and evaluating combinations of targeting groups, therapeutic drugs and linkers.
The conjugates in this study were obtained in good overall yields and demonstrated
significant activity against two breast cancer cell lines. Although one of the compounds (7b)
demonstrated significant antiproliferative activity, it did not, however, demonstrate
enhanced potency compared to the parent drug or selectivity for ER-expressing cells as
compared to non-expressing cells. The results suggest that further modifications in both ER-
targeting strategies and linking groups are needed in order to achieve greater potency and
selectivity in therapeutic drug delivery. The effects of different linkers on both ER binding
and Hsp90 warrant further evaluation as well. Those studies are in progress and will be
described in future publications.
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Proposed extension of research from the antiestrogen-mitomycin C conjugate to the
antiestrogen-Geldanamycin conjugates.
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Approach for synthesis of individual components and assembly as AE-GDA conjugates.
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Synthesis of steroidal antiestrogen component.
Reagents and conditions. (i) CF3COCF3·H2O, H2O2(50%), C5H5N, CH2Cl2, 0°C, 18 h (ii)
TMSiOC6H4MgBr, CuI, THF; 16 h iii. HOAc-H2O (7:3), 1.5 h (iv) TsOCH2CH2OTs,
Cs2CO3, CH3CN, 13 h (v) NaN3, EtOH, 4 h (vi) (HCCHCH2)(CH3)NCH2CH2OH, DEAD,
PS-PPh3, CH3CN, 16 h (vii) Ac2O, AcBr, CH2Cl2, 16 h (viii) NaBH4, MeOH, 1 h (ix)
NaOH, MeOH, 16 h.
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Synthesis of Geldanamycin components.
Reagents and conditions. (i) amine, CH2Cl2, r.t., 24 h (ii) Substituted benzoic acid, SOCl2,
toluene, 70°C, 2 h (iii) CH2Cl2, TEA, 0°C – r.t., 2 h
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Ligation of steroidal antiestrogen and Geldanamycin components using “click” chemistry
Reagents and conditions. (i) CuSO4-5 H2O, sodium ascorbate, t-BuOH-H2O, r.t., 18–70 h
(ii) t-BuOH-H2O, r.t., 24 h
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Table 1
Anti-proliferation activity of ateroidal antiestrogen-Geldanamycin (AE-GDA) Conjugates 7a–7c
Compd MCF-7(IC50) SKBr3(IC50)
5 (GDA) 9.8±0.1 nMa 8.5±1.1 nMa
7a 1150± 90 nM 710±160 nM
7b 102± 4.6 nM 41± 4.6 nM
7c 15200±3000 nM N.D.
IC50 = concentration needed to produce 50% inhibition.
a
ref 15.
N.D. = Not determined.
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